<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="7939">Parthenolide</z:chebi> (PT), a NF-ÎºB inhibitor, has recently been demonstrated as a promising anticancer agent that promotes <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) has been a drug of choice for treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Unfortunately, many of the therapies that use 5-FU alone or in combination with other agents are likely to become ineffective due to drug resistance </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, we investigated the antitumor effect of PT combined with 5-FU on a human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell line, SW620 </plain></SENT>
<SENT sid="4" pm="."><plain>The results demonstrated that combination of PT and 5-FU induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> which was determined using <z:chebi fb="0" ids="53233">MTT</z:chebi>, cell cycle analysis, annexin-V assay, and Hoechst 33258 staining </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> through the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> pathway was confirmed by detecting regulation of Bcl-2 family members, <z:chebi fb="0" ids="4056">cytochrome</z:chebi> C release, and activation of caspase 3 and 9 </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, intra-peritoneal injection of PT and 5-FU showed significant inhibition of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in the <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>These results demonstrate that PT exhibits anticancer activity in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in vitro and in vivo </plain></SENT>
<SENT sid="8" pm="."><plain>These findings provide an efficacious strategy to overcome 5-FU resistance in certain <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>